Differentiating VMAT2 Inhibitors: Long-Term Management and Safety Data That Builds Confidence

This episode, titled 'Differentiating VMAT2 Inhibitors: Long-Term Management and Safety Data That Builds Confidence,' featured panelists discussing the following critical questions:

What factors differentiate vesicular monoamine transporter 2 (VMAT2) inhibitors in terms of long-term management?

How can safety and tolerability data be used to support clinician confidence in prescribing VMAT2 inhibitors?

Led by the moderator, the expert psychiatry pharmacists examined long-term efficacy data for VMAT2 inhibitors, citing study 1506 for valbenazine, which demonstrated sustained benefit over a mean of approximately 19 months, and the RIM-TD study for deutetrabenazine, which showed continued benefit up to 145 weeks. Melissa Cloyd and Jamie Kneebusch discussed key factors that may prompt clinicians to switch between agents over time, including drug interaction profiles, swallowing difficulties, formulation flexibility, and hepatic impairment considerations. The panelists emphasized that both VMAT2 inhibitors are generally well tolerated, with somnolence representing the most common and typically mild, transient side effect, and noted that timing administration around peak drug levels at bedtime can help mitigate this effect, while reassuring clinicians that severe adverse effects such as QTc prolongation and pseudo-Parkinsonism are uncommon and manageable.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Overcoming Payer Barriers and Simplifying Treatment Through Patient Education in Tardive Dyskinesia,' panelists continue their discussion on tardive dyskinesia and highlight strategies for addressing payer-related barriers such as cost and coverage, as well as the role patient education plays in simplifying perceived treatment complexities.